Clinical Trial Update: Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting on the efficacy and safety of KI1001 for insomnia in adults aged 55 and older, with the study focusing on sleep initiation and ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• KI1001

Snippet

Sponsor: Kuhnil Pharmaceutical Co., Ltd. | Conditions: Sleep Initiation and Maintenance Disorders | Phase 3 | Status: COMPLETED